Matches in SemOpenAlex for { <https://semopenalex.org/work/W2017564324> ?p ?o ?g. }
Showing items 1 to 95 of
95
with 100 items per page.
- W2017564324 endingPage "920" @default.
- W2017564324 startingPage "908" @default.
- W2017564324 abstract "Systemic absorption of topical fluorouracil, although usually low, may vary as a result of the specific skin disease, product formulation, and other factors.The present study was conducted to determine the pharmacokinetic profile and tolerability of a new topical 0.5% fluorouracil cream formulation compared with that of a currently available topical formulation of 5% fluorouracil cream.This was an open-label, parallel-group study in which patients with actinic keratosis (AK) were randomized to treatment with either topical 0.5% fluorouracil once daily or topical 5% fluorouracil twice daily for up to 28 days.Twenty-one patients (all white; mean age, 64 years) participated in the study, 11 receiving topical 0.5% fluorouracil and 10 receiving topical 5% fluorouracil. Ten patients receiving 0.5% fluorouracil and 7 patients receiving 5% fluorouracil completed the 28-day study. Plasma concentrations of fluorouracil were detectable in 3 of 10 patients treated with 0.5% fluorouracil and 9 of 10 patients treated with 5% fluorouracil; fluorouracil was detected in the urine of 5 and 9 patients, respectively. Despite the one-tenth difference in drug concentration between formulations, the cumulative amount excreted in the urine of the 0.5% fluorouracil group was approximately one fortieth that of the 5% fluorouracil group. This difference may be a result of variations in vehicle formulations. At least 1 adverse event was reported by 4 of 11 patients in the 0.5% fluorouracil group and all 10 patients in the 5% fluorouracil group. The most common adverse event, facial irritation, was evident with both formulations but reached a plateau during treatment with 0.5% fluorouracil. All patients treated with 0.5% fluorouracil tolerated the full course of therapy, whereas 3 patients in the 5% fluorouracil group discontinued treatment early. No serious treatment-related adverse events were reported.These data suggest that 0.5% fluorouracil has minimal systemic absorption and is well tolerated in patients with AK." @default.
- W2017564324 created "2016-06-24" @default.
- W2017564324 creator A5022350422 @default.
- W2017564324 creator A5046096051 @default.
- W2017564324 creator A5051951766 @default.
- W2017564324 date "2001-06-01" @default.
- W2017564324 modified "2023-10-14" @default.
- W2017564324 title "A pharmacokinetic evaluation of 0.5% and 5% fluorouracil topical cream in patients with actinic keratosis" @default.
- W2017564324 cites W1977308926 @default.
- W2017564324 cites W1979559178 @default.
- W2017564324 cites W1983226581 @default.
- W2017564324 cites W1988934788 @default.
- W2017564324 cites W1991343218 @default.
- W2017564324 cites W2022873215 @default.
- W2017564324 cites W2040053844 @default.
- W2017564324 cites W2043119648 @default.
- W2017564324 cites W2049468550 @default.
- W2017564324 cites W2049807473 @default.
- W2017564324 cites W2057287967 @default.
- W2017564324 cites W2059916616 @default.
- W2017564324 cites W2085903805 @default.
- W2017564324 cites W2094927565 @default.
- W2017564324 cites W2120878621 @default.
- W2017564324 cites W4232205936 @default.
- W2017564324 doi "https://doi.org/10.1016/s0149-2918(01)80078-3" @default.
- W2017564324 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/11440290" @default.
- W2017564324 hasPublicationYear "2001" @default.
- W2017564324 type Work @default.
- W2017564324 sameAs 2017564324 @default.
- W2017564324 citedByCount "57" @default.
- W2017564324 countsByYear W20175643242012 @default.
- W2017564324 countsByYear W20175643242013 @default.
- W2017564324 countsByYear W20175643242014 @default.
- W2017564324 countsByYear W20175643242015 @default.
- W2017564324 countsByYear W20175643242016 @default.
- W2017564324 countsByYear W20175643242017 @default.
- W2017564324 countsByYear W20175643242018 @default.
- W2017564324 countsByYear W20175643242019 @default.
- W2017564324 countsByYear W20175643242021 @default.
- W2017564324 countsByYear W20175643242022 @default.
- W2017564324 countsByYear W20175643242023 @default.
- W2017564324 crossrefType "journal-article" @default.
- W2017564324 hasAuthorship W2017564324A5022350422 @default.
- W2017564324 hasAuthorship W2017564324A5046096051 @default.
- W2017564324 hasAuthorship W2017564324A5051951766 @default.
- W2017564324 hasConcept C112705442 @default.
- W2017564324 hasConcept C126322002 @default.
- W2017564324 hasConcept C141071460 @default.
- W2017564324 hasConcept C16005928 @default.
- W2017564324 hasConcept C197934379 @default.
- W2017564324 hasConcept C2776694085 @default.
- W2017564324 hasConcept C2777873816 @default.
- W2017564324 hasConcept C2778375690 @default.
- W2017564324 hasConcept C2778397455 @default.
- W2017564324 hasConcept C2778648961 @default.
- W2017564324 hasConcept C2780456651 @default.
- W2017564324 hasConcept C3019992690 @default.
- W2017564324 hasConcept C71924100 @default.
- W2017564324 hasConcept C90924648 @default.
- W2017564324 hasConceptScore W2017564324C112705442 @default.
- W2017564324 hasConceptScore W2017564324C126322002 @default.
- W2017564324 hasConceptScore W2017564324C141071460 @default.
- W2017564324 hasConceptScore W2017564324C16005928 @default.
- W2017564324 hasConceptScore W2017564324C197934379 @default.
- W2017564324 hasConceptScore W2017564324C2776694085 @default.
- W2017564324 hasConceptScore W2017564324C2777873816 @default.
- W2017564324 hasConceptScore W2017564324C2778375690 @default.
- W2017564324 hasConceptScore W2017564324C2778397455 @default.
- W2017564324 hasConceptScore W2017564324C2778648961 @default.
- W2017564324 hasConceptScore W2017564324C2780456651 @default.
- W2017564324 hasConceptScore W2017564324C3019992690 @default.
- W2017564324 hasConceptScore W2017564324C71924100 @default.
- W2017564324 hasConceptScore W2017564324C90924648 @default.
- W2017564324 hasIssue "6" @default.
- W2017564324 hasLocation W20175643241 @default.
- W2017564324 hasLocation W20175643242 @default.
- W2017564324 hasOpenAccess W2017564324 @default.
- W2017564324 hasPrimaryLocation W20175643241 @default.
- W2017564324 hasRelatedWork W122076965 @default.
- W2017564324 hasRelatedWork W1979357362 @default.
- W2017564324 hasRelatedWork W201253639 @default.
- W2017564324 hasRelatedWork W2046220168 @default.
- W2017564324 hasRelatedWork W2342092406 @default.
- W2017564324 hasRelatedWork W2344010940 @default.
- W2017564324 hasRelatedWork W2420275899 @default.
- W2017564324 hasRelatedWork W2743189599 @default.
- W2017564324 hasRelatedWork W4200350992 @default.
- W2017564324 hasRelatedWork W4242425288 @default.
- W2017564324 hasVolume "23" @default.
- W2017564324 isParatext "false" @default.
- W2017564324 isRetracted "false" @default.
- W2017564324 magId "2017564324" @default.
- W2017564324 workType "article" @default.